Andrew A Monte1,2,3,4, Brandon Sonn5,6, Jessica Saben5, Barry H Rumack5,7, Kate M Reynolds7, Richard C Dart7, Kennon J Heard5,7. 1. Department of Emergency Medicine, University of Colorado School of Medicine, Aurora, CO, USA. Andrew.monte@cuanschutz.edu. 2. Center for Bioinformatics & Personalized Medicine, University of Colorado School of Medicine, Aurora, CO, USA. Andrew.monte@cuanschutz.edu. 3. Skaggs School of Pharmacy, University of Colorado, Aurora, CO, USA. Andrew.monte@cuanschutz.edu. 4. Rocky Mountain Poison & Drug Center, Denver Health and Hospital Authority, Denver, CO, USA. Andrew.monte@cuanschutz.edu. 5. Department of Emergency Medicine, University of Colorado School of Medicine, Aurora, CO, USA. 6. Skaggs School of Pharmacy, University of Colorado, Aurora, CO, USA. 7. Rocky Mountain Poison & Drug Center, Denver Health and Hospital Authority, Denver, CO, USA.
Abstract
INTRODUCTION: Therapeutic acetaminophen (APAP) ingestion causes asymptomatic drug-induced liver injury in some patients. In most cases, elevations in alanine aminotransferase (ALT) are transient and return to the normal range, even with continued APAP ingestion, though ALT elevation persists in some patients unpredictably. The etiology of this liver injury or adaption is unclear. Our objective was to identify new pharmacogenomic variants associated with elevated ALT or elevated protein adduct concentrations in patients receiving therapeutic acetaminophen. METHODS: We performed genome-wide sequencing analysis on eight patients using leftover blood samples from an observational study that administered four grams of acetaminophen for up to 16 days to all patients. Two patients with ALT elevations > two times the upper limit of normal, two patients with no adduct formation, and four control patients were sequenced. The genomes were aligned with the GRCh38 reference sequence, and variants with predicted low, moderate, or high impact on the subsequent proteins were first manually curated for biologic plausibility, then organized and examined in the REACTOME pathway analysis program. RESULTS: We found 394 variants in 107 genes associated with elevated ALT. Variants associated with ALT elevation predominantly involved genes in the immune system (MHC class II complex genes), endoplasmic reticulum stress response (SEC23B and XBP1), oxidative phosphorylation (NDUFB9), and WNT/beta-catenin signaling (FZD5). Variants associated with elevated adducts were primarily in signal transduction (MUC20) and DNA repair mechanisms (P53). CONCLUSIONS: While underpowered, genetic variants in immune system genes may be associated with drug-induced liver injury at therapeutic doses of acetaminophen.
INTRODUCTION: Therapeutic acetaminophen (APAP) ingestion causes asymptomatic drug-induced liver injury in some patients. In most cases, elevations in alanine aminotransferase (ALT) are transient and return to the normal range, even with continued APAP ingestion, though ALT elevation persists in some patients unpredictably. The etiology of this liver injury or adaption is unclear. Our objective was to identify new pharmacogenomic variants associated with elevated ALT or elevated protein adduct concentrations in patients receiving therapeutic acetaminophen. METHODS: We performed genome-wide sequencing analysis on eight patients using leftover blood samples from an observational study that administered four grams of acetaminophen for up to 16 days to all patients. Two patients with ALT elevations > two times the upper limit of normal, two patients with no adduct formation, and four control patients were sequenced. The genomes were aligned with the GRCh38 reference sequence, and variants with predicted low, moderate, or high impact on the subsequent proteins were first manually curated for biologic plausibility, then organized and examined in the REACTOME pathway analysis program. RESULTS: We found 394 variants in 107 genes associated with elevated ALT. Variants associated with ALT elevation predominantly involved genes in the immune system (MHC class II complex genes), endoplasmic reticulum stress response (SEC23B and XBP1), oxidative phosphorylation (NDUFB9), and WNT/beta-catenin signaling (FZD5). Variants associated with elevated adducts were primarily in signal transduction (MUC20) and DNA repair mechanisms (P53). CONCLUSIONS: While underpowered, genetic variants in immune system genes may be associated with drug-induced liver injury at therapeutic doses of acetaminophen.
Entities:
Keywords:
ALT; Acetaminophen; Drug induced liver injury; Hepatotoxicity; Pharmacogenomics
Authors: Shane C Wright; Maria Consuelo Alonso Cañizal; Tobias Benkel; Katharina Simon; Christian Le Gouill; Pierre Matricon; Yoon Namkung; Viktoria Lukasheva; Gabriele M König; Stéphane A Laporte; Jens Carlsson; Evi Kostenis; Michel Bouvier; Gunnar Schulte; Carsten Hoffmann Journal: Sci Signal Date: 2018-12-04 Impact factor: 8.192
Authors: M L Hautekeete; Y Horsmans; C Van Waeyenberge; C Demanet; J Henrion; L Verbist; R Brenard; C Sempoux; P P Michielsen; P S Yap; J Rahier; A P Geubel Journal: Gastroenterology Date: 1999-11 Impact factor: 22.682
Authors: Jian Jiang; Jacob J Briedé; Danyel G J Jennen; Anke Van Summeren; Karen Saritas-Brauers; Gert Schaart; Jos C S Kleinjans; Theo M C M de Kok Journal: Toxicol Lett Date: 2015-02-19 Impact factor: 4.372
Authors: Timothy J Davern; Laura P James; Jack A Hinson; Julie Polson; Anne M Larson; Robert J Fontana; Ezmina Lalani; Santiago Munoz; A Obaid Shakil; William M Lee Journal: Gastroenterology Date: 2006-03 Impact factor: 22.682
Authors: Michael H Court; Marina Freytsis; Xueding Wang; Inga Peter; Chantal Guillemette; Suwagmani Hazarika; Su X Duan; David J Greenblatt; William M Lee Journal: J Pharmacol Exp Ther Date: 2013-02-13 Impact factor: 4.030